thexyldimethylsilyl 2-azido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside | 478920-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃二恶英
• 英文名称: thexyldimethylsilyl 2-azido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside
• 英文别名: (4aR,6S,7R,8R,8aS)-7-azido-6-[2,3-dimethylbutan-2-yl(dimethyl)silyl]oxy-2,2-dimethyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-ol
• CAS: 478920-14-8
• 化学式: C₁₇H₃₃N₃O₅Si
• 分子量: 387.552
• InChiKey: UVOKTUWBIVONGN-RYPNDVFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.56
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  thexyldimethylsilyl 2-azido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside 在 lithium hydroxide 、 sodium hydride 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 thexyldimethylsilyl 2-azido-2-deoxy-4,6-O-isopropylidene-3-O-[(2R)-propionyl-(L-alanine methyl ester)-2-yl]-β-D-glucopyranoside
  参考文献：
  名称：

  Synthesis of Muramyl Peptides Containing meso-Diaminopimelic Acid

  摘要：

  Chain-extension Of L-glutamate aldehyde 3 by means of the Wittig-Homer reaction furnished the desired C-7 dicarboxylic acid derivative, which in turn, after C-C double bond hydrogenation and protecting group manipulation, afforded the 2,6-diaminopimelic acid derivatives (S,R)-9 and (S,S)-9, both with the desired orthogonal protecting group pattern. Synthesis of the muramic acid derivative 15 and attachment of an L-alanine residue furnished muramyl-L-alanine 18. The corresponding 1,6-anhydromuramic acid derivative 26 was obtained similarly. Treatment of these compounds with peptides 28-30 and with the 2,6-diaminopimelic acid containing di- and tripeptides 32a, 32b, and 35 gave the protected muramyl peptides 17, 37, 40, 42, 44, 46, and 49a and 49b, which, after deprotection, afforded the desired target molecules muramyl-L-alanine (38), muramyl-L-alanyl-D-glutamic acid (39), muramyl-L-alanyl-D-glutaminide (41), muramyl-L-alanyl-D-isoglutaminyl-L-lysine (43), muramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (45), muramyl-L-alanylL-isoglutaminyl-(2S,6R)-2,6-dian-Anopimelinyl-D-alanine (47), 1,6-anhydromuramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (50a), and 1,6-anhydromuramyl-L-alanyl-Disoglutaminyl-(2S,6S)-2,6-diaminiopimelic acid (50b). (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.

  DOI：

  10.1002/1099-0690(200208)2002:16<2710::aid-ejoc2710>3.0.co;2-8
• 作为产物：
  描述：

  2,2-二甲氧基丙烷 、 thexyldimethylsilyl 2-azido-2-deoxy-β-D-glucopyranoside 在 对甲苯磺酸 作用下， 以98%的产率得到thexyldimethylsilyl 2-azido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside
  参考文献：
  名称：

  Synthesis of Muramyl Peptides Containing meso-Diaminopimelic Acid

  摘要：

  Chain-extension Of L-glutamate aldehyde 3 by means of the Wittig-Homer reaction furnished the desired C-7 dicarboxylic acid derivative, which in turn, after C-C double bond hydrogenation and protecting group manipulation, afforded the 2,6-diaminopimelic acid derivatives (S,R)-9 and (S,S)-9, both with the desired orthogonal protecting group pattern. Synthesis of the muramic acid derivative 15 and attachment of an L-alanine residue furnished muramyl-L-alanine 18. The corresponding 1,6-anhydromuramic acid derivative 26 was obtained similarly. Treatment of these compounds with peptides 28-30 and with the 2,6-diaminopimelic acid containing di- and tripeptides 32a, 32b, and 35 gave the protected muramyl peptides 17, 37, 40, 42, 44, 46, and 49a and 49b, which, after deprotection, afforded the desired target molecules muramyl-L-alanine (38), muramyl-L-alanyl-D-glutamic acid (39), muramyl-L-alanyl-D-glutaminide (41), muramyl-L-alanyl-D-isoglutaminyl-L-lysine (43), muramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (45), muramyl-L-alanylL-isoglutaminyl-(2S,6R)-2,6-dian-Anopimelinyl-D-alanine (47), 1,6-anhydromuramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (50a), and 1,6-anhydromuramyl-L-alanyl-Disoglutaminyl-(2S,6S)-2,6-diaminiopimelic acid (50b). (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.

  DOI：

  10.1002/1099-0690(200208)2002:16<2710::aid-ejoc2710>3.0.co;2-8

文献信息

• Synthetic lipid A derivative
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US09309276B2

  公开（公告）日：2016-04-12

  The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative.

  这项发明提供了适用于合成脂多糖A衍生物的功能化单糖和双糖，以及合成和使用合成脂多糖A衍生物的方法。
• Innate Immune Responses of Synthetic Lipid A Derivatives ofNeisseria meningitidis
  作者：Yanghui Zhang、Jidnyasa Gaekwad、Margreet A. Wolfert、Geert-Jan Boons

  DOI：10.1002/chem.200701165

  日期：2008.1.7

  macrophages were exposed to the synthetic compound and its parent LOS, E. coli lipid A (2), and a hybrid derivative (4) that has the asymmetrical acylation pattern of E. coli lipid A, but the shorter lipids of meningococcal lipid A. The resulting supernatants were examined for tumor necrosis factor alpha (TNF-alpha) and interferon beta (IFN-beta) production. The lipid A derivative containing KDO was much more

  脑膜炎奈瑟菌脂多糖 (LOS) 和大肠杆菌脂多糖 (LPS) 的脂质 A 的脂肪酸模式和化学性质的差异可能是炎症特性差异的原因。此外，有迹象表明 LOS 和 LPS 的二聚 3-脱氧-D-甘露糖-oct-2-ulosonic 酸 (KDO) 部分增强了生物活性。脂质 A 结构的异质性和可能与其他炎症成分的污染使得这些观察结果难以证实。为了解决这些问题，已经开发了一种高度收敛的合成含有 KDO 的脂质 A 衍生物的方法，该方法依赖于以顺序方式选择性去除或揭露异亚丙基缩醛、9-芴基甲氧基羰基 (Fmoc)、烯丙氧基碳酸酯的能力。 Alloc)、叠氮化物、和二甲基甲硅烷基 (TDS) 醚。该策略用于合成含有 KDO 的脑膜炎奈瑟球菌脂质 A (3)。小鼠巨噬细胞暴露于合成化合物及其亲本 LOS、大肠杆菌脂质 A (2) 和具有大肠杆菌脂质 A 不对称酰化模式但脑膜炎球菌脂质 A 的较短脂质的杂化衍生物
• Synthesis of Muramyl Peptides Containing meso-Diaminopimelic Acid
  作者：Niels Kubasch、Richard R. Schmidt

  DOI：10.1002/1099-0690(200208)2002:16<2710::aid-ejoc2710>3.0.co;2-8

  日期：2002.8

  Chain-extension Of L-glutamate aldehyde 3 by means of the Wittig-Homer reaction furnished the desired C-7 dicarboxylic acid derivative, which in turn, after C-C double bond hydrogenation and protecting group manipulation, afforded the 2,6-diaminopimelic acid derivatives (S,R)-9 and (S,S)-9, both with the desired orthogonal protecting group pattern. Synthesis of the muramic acid derivative 15 and attachment of an L-alanine residue furnished muramyl-L-alanine 18. The corresponding 1,6-anhydromuramic acid derivative 26 was obtained similarly. Treatment of these compounds with peptides 28-30 and with the 2,6-diaminopimelic acid containing di- and tripeptides 32a, 32b, and 35 gave the protected muramyl peptides 17, 37, 40, 42, 44, 46, and 49a and 49b, which, after deprotection, afforded the desired target molecules muramyl-L-alanine (38), muramyl-L-alanyl-D-glutamic acid (39), muramyl-L-alanyl-D-glutaminide (41), muramyl-L-alanyl-D-isoglutaminyl-L-lysine (43), muramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (45), muramyl-L-alanylL-isoglutaminyl-(2S,6R)-2,6-dian-Anopimelinyl-D-alanine (47), 1,6-anhydromuramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (50a), and 1,6-anhydromuramyl-L-alanyl-Disoglutaminyl-(2S,6S)-2,6-diaminiopimelic acid (50b). (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.